Acute Telogen Effluvium in Patients Recently Infected with SARS-CoV-2

Abstract: Introduction: The hair cycle is especially susceptible to endogenous and exogenous stimuli, including febrile states and emotional stress, which are a constant in this pandemic era. In this case series, we describe the clinical characteristics of patients recently diagnosed with SARS-CoV-2 infection who developed acute telogen effluvium. Material and Methods: We performed a registry of patients with laboratory-confirmed SARS-CoV-2 infection who developed acute telogen effluvium and actively sought medical care at the Hair Unit of Dermatology Center of CUF Descobertas Hospital, from March 2020 to October 2020. Patient demographics, the month of SARS-CoV-2 infection diagnosis, COVID-19 associated symptoms, latency of telogen effluvium, duration of hair loss, and associated scalp symptoms were recorded. Results: Twenty-seven patients recently diagnosed with SARS-CoV-2 infection presented with acute telogen effluvium. Of them, 5 (18.5%) patients mentioned trichodynia. The median time of latency of increased hair loss since SARS-CoV-2 infection diagnosis was 10 weeks. In a third of cases (n=9, 33.3%), hair loss occurred early (with a latency period of 3 weeks or less). The resolution of telogen effluvium was documented in 16 (59%) cases with a median duration of hair loss of 24.5 days. The most common symptoms of COVID-19 were fever (n=17, 63%), ageusia (n=8, 30%), cough (n=6, 22%), myalgia (n=5, 18.5%), anosmia (n=4, 15%), and thoracalgia (n=3, 11%). Four patients (15%) with SARS-CoV-2 infection were asymptomatic for COVID-19. Discussion: Acute telogen effluvium corresponds to a delayed consequence of an abnormal shift in the hair cycle from anagen to telogen, which is responsible for premature hair shedding, occurring approximately two to three months after a triggering event. Viral illnesses and febrile states are known causes. Regarding SARS-CoV-2 infection, we hypothesize that viral cytopathic effects and inflammatory or immune responses may affect hair follicles and explain hair loss and trichodynia. Conclusion: Our case series presents the first comprehensive collection of patients with acute telogen effluvium following SARS-CoV-2 infection. Interestingly, in a third of our cases, telogen effluvium developed within the first 3 weeks of SARS-CoV-2 infection. Based on these data, we propose that this finding should be considered in COVID-19, especially at the convalescent phase.

Saved in:
Bibliographic Details
Main Authors: Roda,Â, Oliveira-Soares,R
Format: Digital revista
Language:English
Published: Sociedade Portuguesa de Dermatologia e Venereologia 2021
Online Access:http://scielo.pt/scielo.php?script=sci_arttext&pid=S2182-23952021000100011
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2182-23952021000100011
record_format ojs
spelling oai:scielo:S2182-239520210001000112022-02-24Acute Telogen Effluvium in Patients Recently Infected with SARS-CoV-2Roda,ÂOliveira-Soares,R Alopecia COVID-19 Coronavirus Infections SARS-CoV-2 Abstract: Introduction: The hair cycle is especially susceptible to endogenous and exogenous stimuli, including febrile states and emotional stress, which are a constant in this pandemic era. In this case series, we describe the clinical characteristics of patients recently diagnosed with SARS-CoV-2 infection who developed acute telogen effluvium. Material and Methods: We performed a registry of patients with laboratory-confirmed SARS-CoV-2 infection who developed acute telogen effluvium and actively sought medical care at the Hair Unit of Dermatology Center of CUF Descobertas Hospital, from March 2020 to October 2020. Patient demographics, the month of SARS-CoV-2 infection diagnosis, COVID-19 associated symptoms, latency of telogen effluvium, duration of hair loss, and associated scalp symptoms were recorded. Results: Twenty-seven patients recently diagnosed with SARS-CoV-2 infection presented with acute telogen effluvium. Of them, 5 (18.5%) patients mentioned trichodynia. The median time of latency of increased hair loss since SARS-CoV-2 infection diagnosis was 10 weeks. In a third of cases (n=9, 33.3%), hair loss occurred early (with a latency period of 3 weeks or less). The resolution of telogen effluvium was documented in 16 (59%) cases with a median duration of hair loss of 24.5 days. The most common symptoms of COVID-19 were fever (n=17, 63%), ageusia (n=8, 30%), cough (n=6, 22%), myalgia (n=5, 18.5%), anosmia (n=4, 15%), and thoracalgia (n=3, 11%). Four patients (15%) with SARS-CoV-2 infection were asymptomatic for COVID-19. Discussion: Acute telogen effluvium corresponds to a delayed consequence of an abnormal shift in the hair cycle from anagen to telogen, which is responsible for premature hair shedding, occurring approximately two to three months after a triggering event. Viral illnesses and febrile states are known causes. Regarding SARS-CoV-2 infection, we hypothesize that viral cytopathic effects and inflammatory or immune responses may affect hair follicles and explain hair loss and trichodynia. Conclusion: Our case series presents the first comprehensive collection of patients with acute telogen effluvium following SARS-CoV-2 infection. Interestingly, in a third of our cases, telogen effluvium developed within the first 3 weeks of SARS-CoV-2 infection. Based on these data, we propose that this finding should be considered in COVID-19, especially at the convalescent phase.info:eu-repo/semantics/openAccessSociedade Portuguesa de Dermatologia e VenereologiaRevista da Sociedade Portuguesa de Dermatologia e Venereologia v.79 n.1 20212021-03-01info:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2182-23952021000100011en10.29021/spdv.79.1.1299
institution SCIELO
collection OJS
country Portugal
countrycode PT
component Revista
access En linea
databasecode rev-scielo-pt
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Roda,Â
Oliveira-Soares,R
spellingShingle Roda,Â
Oliveira-Soares,R
Acute Telogen Effluvium in Patients Recently Infected with SARS-CoV-2
author_facet Roda,Â
Oliveira-Soares,R
author_sort Roda,Â
title Acute Telogen Effluvium in Patients Recently Infected with SARS-CoV-2
title_short Acute Telogen Effluvium in Patients Recently Infected with SARS-CoV-2
title_full Acute Telogen Effluvium in Patients Recently Infected with SARS-CoV-2
title_fullStr Acute Telogen Effluvium in Patients Recently Infected with SARS-CoV-2
title_full_unstemmed Acute Telogen Effluvium in Patients Recently Infected with SARS-CoV-2
title_sort acute telogen effluvium in patients recently infected with sars-cov-2
description Abstract: Introduction: The hair cycle is especially susceptible to endogenous and exogenous stimuli, including febrile states and emotional stress, which are a constant in this pandemic era. In this case series, we describe the clinical characteristics of patients recently diagnosed with SARS-CoV-2 infection who developed acute telogen effluvium. Material and Methods: We performed a registry of patients with laboratory-confirmed SARS-CoV-2 infection who developed acute telogen effluvium and actively sought medical care at the Hair Unit of Dermatology Center of CUF Descobertas Hospital, from March 2020 to October 2020. Patient demographics, the month of SARS-CoV-2 infection diagnosis, COVID-19 associated symptoms, latency of telogen effluvium, duration of hair loss, and associated scalp symptoms were recorded. Results: Twenty-seven patients recently diagnosed with SARS-CoV-2 infection presented with acute telogen effluvium. Of them, 5 (18.5%) patients mentioned trichodynia. The median time of latency of increased hair loss since SARS-CoV-2 infection diagnosis was 10 weeks. In a third of cases (n=9, 33.3%), hair loss occurred early (with a latency period of 3 weeks or less). The resolution of telogen effluvium was documented in 16 (59%) cases with a median duration of hair loss of 24.5 days. The most common symptoms of COVID-19 were fever (n=17, 63%), ageusia (n=8, 30%), cough (n=6, 22%), myalgia (n=5, 18.5%), anosmia (n=4, 15%), and thoracalgia (n=3, 11%). Four patients (15%) with SARS-CoV-2 infection were asymptomatic for COVID-19. Discussion: Acute telogen effluvium corresponds to a delayed consequence of an abnormal shift in the hair cycle from anagen to telogen, which is responsible for premature hair shedding, occurring approximately two to three months after a triggering event. Viral illnesses and febrile states are known causes. Regarding SARS-CoV-2 infection, we hypothesize that viral cytopathic effects and inflammatory or immune responses may affect hair follicles and explain hair loss and trichodynia. Conclusion: Our case series presents the first comprehensive collection of patients with acute telogen effluvium following SARS-CoV-2 infection. Interestingly, in a third of our cases, telogen effluvium developed within the first 3 weeks of SARS-CoV-2 infection. Based on these data, we propose that this finding should be considered in COVID-19, especially at the convalescent phase.
publisher Sociedade Portuguesa de Dermatologia e Venereologia
publishDate 2021
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2182-23952021000100011
work_keys_str_mv AT rodaa acutetelogeneffluviuminpatientsrecentlyinfectedwithsarscov2
AT oliveirasoaresr acutetelogeneffluviuminpatientsrecentlyinfectedwithsarscov2
_version_ 1756003683706863616